These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 38010712)

  • 1. Multiple Sclerosis Progression and Relapse Activity in Children.
    Iaffaldano P; Portaccio E; Lucisano G; Simone M; Manni A; Guerra T; Paolicelli D; Betti M; De Meo E; Pastò L; Razzolini L; Rocca MA; Ferrè L; Brescia Morra V; Patti F; Zaffaroni M; Gasperini C; De Luca G; Ferraro D; Granella F; Pozzilli C; Romano S; Gallo P; Bergamaschi R; Coniglio MG; Lus G; Vianello M; Banfi P; Lugaresi A; Totaro R; Spitaleri D; Cocco E; Di Palma F; Maimone D; Valentino P; Torri Clerici V; Protti A; Maniscalco GT; Salemi G; Pesci I; Aguglia U; Lepore V; Filippi M; Trojano M; Amato MP;
    JAMA Neurol; 2024 Jan; 81(1):50-58. PubMed ID: 38010712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis.
    Simone M; Lucisano G; Guerra T; Paolicelli D; Rocca MA; Brescia Morra V; Patti F; Annovazzi P; Gasperini C; De Luca G; Ferraro D; Margari L; Granella F; Pozzilli C; Romano S; Perini P; Bergamaschi R; Coniglio MG; Lus G; Vianello M; Lugaresi A; Portaccio E; Filippi M; Amato MP; Iaffaldano P;
    J Neurol; 2024 Oct; 271(10):6782-6790. PubMed ID: 39179712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
    Kappos L; Wolinsky JS; Giovannoni G; Arnold DL; Wang Q; Bernasconi C; Model F; Koendgen H; Manfrini M; Belachew S; Hauser SL
    JAMA Neurol; 2020 Sep; 77(9):1132-1140. PubMed ID: 32511687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis.
    Tur C; Carbonell-Mirabent P; Cobo-Calvo Á; Otero-Romero S; Arrambide G; Midaglia L; Castilló J; Vidal-Jordana Á; Rodríguez-Acevedo B; Zabalza A; Galán I; Nos C; Salerno A; Auger C; Pareto D; Comabella M; Río J; Sastre-Garriga J; Rovira À; Tintoré M; Montalban X
    JAMA Neurol; 2023 Feb; 80(2):151-160. PubMed ID: 36534392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
    Mouresan EF; Mentesidou E; Berglund A; McKay KA; Hillert J; Iacobaeus E
    Neurology; 2024 Mar; 102(6):e208051. PubMed ID: 38394472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High NEDA and No PIRA in Natalizumab-Treated Patients With Pediatric-Onset Multiple Sclerosis.
    Puthenparampil M; Gaggiola M; Ponzano M; Zanotelli G; Miscioscia A; Nosadini M; Di Paola A; Sartori S; Perini P; Rinaldi F; Bovis F; Gallo P
    Neurol Neuroimmunol Neuroinflamm; 2024 Sep; 11(5):e200303. PubMed ID: 39141876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of secondary progressive multiple sclerosis after early worsening of disability.
    Dzau W; Sharmin S; Patti F; Izquierdo G; Eichau S; Prat A; Girard M; Duquette P; Onofrj M; Lugaresi A; Ozakbas S; Gerlach O; Boz C; Grammond P; Terzi M; Amato MP; La Spitaleri D; Ramo-Tello C; Maimone D; Cartechini E; Buzzard K; Skibina O; van der Walt A; Butzkueven H; Iuliano G; Soysal A; Kalincik T
    J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):984-991. PubMed ID: 37414538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Cognitive Outcomes in Patients With Pediatric-Onset vs Adult-Onset Multiple Sclerosis.
    McKay KA; Manouchehrinia A; Berrigan L; Fisk JD; Olsson T; Hillert J
    JAMA Neurol; 2019 Sep; 76(9):1028-1034. PubMed ID: 31206130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
    Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
    Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What an adult multiple sclerosis registry can tell us about pediatric onset multiple sclerosis?
    Alkolfat F; Said S; Mekky J; Eldeeb H
    Mult Scler Relat Disord; 2023 Nov; 79():104962. PubMed ID: 37714097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis.
    Gavoille A; Rollot F; Casey R; Kerbrat A; Le Page E; Bigaut K; Mathey G; Michel L; Ciron J; Ruet A; Maillart E; Labauge P; Zephir H; Papeix C; Defer G; Lebrun-Frenay C; Moreau T; Berger E; Stankoff B; Clavelou P; Thouvenot E; Heinzlef O; Pelletier J; Al-Khedr A; Casez O; Bourre B; Cabre P; Wahab A; Magy L; Camdessanché JP; Doghri I; Moulin S; Ben-Nasr H; Labeyrie C; Hankiewicz K; Neau JP; Pottier C; Nifle C; Manchon E; Lapergue B; Wiertlewski S; De Sèze J; Vukusic S; Laplaud DA;
    JAMA Neurol; 2024 Aug; 81(8):814-823. PubMed ID: 38949816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Clinical Relapses With Disease Outcomes in Multiple Sclerosis Patients Older Than 50 Years.
    Pfeuffer S; Wolff S; Aslan D; Rolfes L; Korsen M; Pawlitzki M; Albrecht P; Havla J; Huttner HB; Kleinschnitz C; Meuth SG; Pul R; Ruck T
    Neurology; 2024 Jul; 103(2):e209574. PubMed ID: 38870471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.
    Portaccio E; Betti M; De Meo E; Addazio I; Pastò L; Razzolini L; Totaro R; Spitaleri D; Lugaresi A; Cocco E; Onofrj M; Di Palma F; Patti F; Maimone D; Valentino P; Torri Clerici V; Protti A; Ferraro D; Lus G; Maniscalco GT; Brescia Morra V; Salemi G; Granella F; Pesci I; Bergamaschi R; Aguglia U; Vianello M; Simone M; Lepore V; Iaffaldano P; Comi G; Filippi M; Trojano M; Amato MP;
    J Neurol; 2024 Aug; 271(8):5074-5082. PubMed ID: 38805052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis.
    Baroncini D; Simone M; Iaffaldano P; Brescia Morra V; Lanzillo R; Filippi M; Romeo M; Patti F; Chisari CG; Cocco E; Fenu G; Salemi G; Ragonese P; Inglese M; Cellerino M; Margari L; Comi G; Zaffaroni M; Ghezzi A;
    JAMA Neurol; 2021 Jun; 78(6):726-735. PubMed ID: 33938921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis.
    Cagol A; Schaedelin S; Barakovic M; Benkert P; Todea RA; Rahmanzadeh R; Galbusera R; Lu PJ; Weigel M; Melie-Garcia L; Ruberte E; Siebenborn N; Battaglini M; Radue EW; Yaldizli Ö; Oechtering J; Sinnecker T; Lorscheider J; Fischer-Barnicol B; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Chan A; Salmen A; Pot C; Bridel C; Zecca C; Derfuss T; Lieb JM; Remonda L; Wagner F; Vargas MI; Du Pasquier R; Lalive PH; Pravatà E; Weber J; Cattin PC; Gobbi C; Leppert D; Kappos L; Kuhle J; Granziera C
    JAMA Neurol; 2022 Jul; 79(7):682-692. PubMed ID: 35575778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A longitudinal study of pediatric-onset multiple sclerosis in the Voronezh region].
    Bykova VA; Ermolenko NA; Krasnorutskaya ON; Zolotarev OV; Shiryaev OY; Bragina OV; Abramova MR
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(9. Vyp. 2):100-104. PubMed ID: 37942980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
    Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How patients with multiple sclerosis acquire disability.
    Lublin FD; Häring DA; Ganjgahi H; Ocampo A; Hatami F; Čuklina J; Aarden P; Dahlke F; Arnold DL; Wiendl H; Chitnis T; Nichols TE; Kieseier BC; Bermel RA
    Brain; 2022 Sep; 145(9):3147-3161. PubMed ID: 35104840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis.
    Benallegue N; Rollot F; Wiertlewski S; Casey R; Debouverie M; Kerbrat A; De Seze J; Ciron J; Ruet A; Labauge P; Maillart E; Zephir H; Papeix C; Defer G; Lebrun-Frenay C; Moreau T; Berger E; Stankoff B; Clavelou P; Heinzlef O; Pelletier J; Thouvenot E; Al Khedr A; Bourre B; Casez O; Cabre P; Wahab A; Magy L; Vukusic S; Laplaud DA;
    JAMA Neurol; 2024 Mar; 81(3):273-282. PubMed ID: 38345791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials.
    Ingwersen J; Masanneck L; Pawlitzki M; Samadzadeh S; Weise M; Aktas O; Meuth SG; Albrecht P
    Sci Rep; 2023 Sep; 13(1):15003. PubMed ID: 37696848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.